Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2023 | Update on parsaclisib in patients with R/R FL treated in the CITADEL-203 trial

Ryan Lynch, MD, Seattle Cancer Care Alliance, University of Washington, Seattle, WA, provides an update on the CITADEL-203 trial (NCT03126019) investigating parsaclisib monotherapy in patients with relapsed/refractory (R/R) follicular lymphoma (FL) who had received at least two prior lines of therapy. Although the safety profile of this PI3Kδ inhibitor was manageable and durable responses were observed in patients, recent safety concerns regarding this drug class have meant that approval of the drug is unlikely. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Research Funding: Seagen Inc., Rapt, Cyteir, Incyte, Genentech, Bayer, TG Therapeutics, Merck
Consultancy: Cancer Study Group, SeaGen, Foresight Diagnostics, Abbvie